{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06144554",
            "orgStudyIdInfo": {
                "id": "Post-Market Registry"
            },
            "organization": {
                "fullName": "Insulet Corporation",
                "class": "INDUSTRY"
            },
            "briefTitle": "Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes",
            "officialTitle": "Post Market Registry to Collect Real-World Safety and Effectiveness Data for the Omnipod 5 System in Children and Adults With Type 1 Diabetes",
            "therapeuticArea": [
                "Endocrinology"
            ],
            "study": "post-market-registry-for-the-omnipod-system-in-children-and-adults-with-type-diabetes"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-11",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-09-25",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-09-25",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-01-28",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-11-10",
            "studyFirstSubmitQcDate": "2023-11-16",
            "studyFirstPostDateStruct": {
                "date": "2023-11-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-11-21",
            "lastUpdatePostDateStruct": {
                "date": "2023-11-28",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Insulet Corporation",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": true,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This is a decentralized observational clinical registry to collect real-world evidence related to the safety and effectiveness of the Omnipod 5 system in children and adults with Type 1 Diabetes.",
            "detailedDescription": "This is a decentralized observational clinical registry to collect real-world evidence related to the safety and effectiveness of the Omnipod 5 system in children and adults with Type 1 Diabetes.\n\nA minimum of 2,200 Type 1 participants will be recruited to ensure a minimum of 1,650 participants completing 12 months of follow-up. The minimum number of completed participants is as follows:\n\n* 150 participants aged 2-5\n* 300 participants aged 6-13\n* 300 participants aged 14-17\n* 900 participants aged 18+\n\nIn addition to the enrollment targets above, a minimum of 1100 Omnipod-na\u00efve users, 880 pump-na\u00efve users, and 110 CGM-na\u00efve users will be recruited.\n\nParticipants are expected to be followed for 12 months."
        },
        "conditionsModule": {
            "conditions": [
                "Type 1 Diabetes"
            ],
            "keywords": [
                "Type 1 Diabetes",
                "Omnipod",
                "Automated Insulin Delivery",
                "Registry"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 2200,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Omnipod User",
                    "description": "All new users for the Omnipod 5 System will be required to register with Insulet's Podder Central. Users already in Podder Central will be required to log into their account before logging into the Omnipod 5 Controller if transitioning to the Omnipod 5 System. As part of the onboarding process, users will be invited to participate in this registry.",
                    "interventionNames": [
                        "Device: Omnipod 5"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DEVICE",
                    "name": "Omnipod 5",
                    "description": "The Omnipod 5 System consists of a tubeless insulin Pod and the Omnipod\u00ae 5 App, installed on a designated Controller or compatible Android smartphone. The Omnipod 5 System works with the Dexcom G6\u00ae Continuous Glucose Monitoring System to continuously adapt and automatically deliver insulin according to personal needs.\n\nEvery two weeks while on the Omnipod 5 system, participants will receive a push notification to complete assessments including any severe hypoglycemia or diabetic ketoacidosis events experienced since the prior assessment.",
                    "armGroupLabels": [
                        "Omnipod User"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence rate of severe hypoglycemia",
                    "description": "Measures frequency of severe hypoglycemia",
                    "timeFrame": "From baseline to study completion, up to 12 months."
                },
                {
                    "measure": "Incidence rate of DKA",
                    "description": "Measures frequency of DKA",
                    "timeFrame": "From baseline to study completion, up to 12 months."
                },
                {
                    "measure": "A1c at 3, 6, 9 and 12 months",
                    "description": "Measures device effectiveness",
                    "timeFrame": "Comparing the change in A1c at baseline compared to at 3, 6, 9 and 12 months"
                },
                {
                    "measure": "Percentage of time < 54 mg/dL",
                    "description": "Glucose metric from study continuous glucose monitoring system",
                    "timeFrame": "From baseline to study completion, up to 12 months"
                },
                {
                    "measure": "Percentage of time < 70 mg/dL",
                    "description": "Glucose metric from study continuous glucose monitoring system",
                    "timeFrame": "From baseline to study completion, up to 12 months"
                },
                {
                    "measure": "Percentage of time > 180 mg/dL",
                    "description": "Glucose metric from study continuous glucose monitoring system",
                    "timeFrame": "From baseline to study completion, up to 12 months"
                },
                {
                    "measure": "Percentage of time > 250 mg/dL",
                    "description": "Glucose metric from study continuous glucose monitoring system",
                    "timeFrame": "From baseline to study completion, up to 12 months"
                },
                {
                    "measure": "Percentage of time in range 70-180 mg/dL",
                    "description": "Glucose metric from study continuous glucose monitoring system",
                    "timeFrame": "From baseline to study completion, up to 12 months"
                },
                {
                    "measure": "Mean Glucose mg/dL",
                    "description": "Glucose metric from study continuous glucose monitoring system",
                    "timeFrame": "From baseline to study completion, up to 12 months"
                },
                {
                    "measure": "Standard deviation of glucose mg/dL",
                    "description": "measure of the range of glucose readings",
                    "timeFrame": "From baseline to study completion, about 12 months"
                },
                {
                    "measure": "Glucose management indicator %",
                    "description": "MI tells you what your approximate A1C level is likely to be, based on the average glucose level from your CGM readings for 14 or more days.",
                    "timeFrame": "From baseline to study completion, up to 12 months"
                },
                {
                    "measure": "Percentage of participants achieving A1C < 7%",
                    "description": "measurement of percentage of participants with A1c less than 7%",
                    "timeFrame": "From baseline to study completion, up to 12 months"
                },
                {
                    "measure": "Percentage of participants with time in range > 70%",
                    "description": "measurement of percentage of participants with time in range \\> 70%",
                    "timeFrame": "From baseline to study completion, up to12 months"
                },
                {
                    "measure": "Percentage of participants with time below range (<70mg/dL) of < 4%",
                    "description": "measurement of percentage of participants with time below range (\\<70mg/dL) of \\< 4%",
                    "timeFrame": "From baseline to study completion, up to 12 months"
                },
                {
                    "measure": "Insulin Usage",
                    "description": "Measure of insulin requirements",
                    "timeFrame": "From baseline to study completion, up to 12 months"
                },
                {
                    "measure": "Body Mass Index (BMI) or BMI z-score",
                    "description": "Changes in body mass index",
                    "timeFrame": "at 6 months and at the end of registry participation, up to 12 months."
                },
                {
                    "measure": "EQ-5D (inclusive of the Visual Analogue Scale (VAS))",
                    "description": "Questionaire",
                    "timeFrame": "at baseline, at 6 months and at the end of registry participation, up to 12 months."
                },
                {
                    "measure": "Insulin Delivery Systems: Perceptions, Ideas, Reflections, and Expectations (INSPIRE)",
                    "description": "Questionaire",
                    "timeFrame": "at baseline, at 6 months and at the end of registry participation, up to 12 months"
                },
                {
                    "measure": "System Usability Scale (SUS)",
                    "description": "Questionnaire",
                    "timeFrame": "at baseline, at 6 months and at the end of registry participation, up to 12 months"
                },
                {
                    "measure": "Incidence rate of prolonged hyperglycemia (events per person months) during usage of Activity Feature",
                    "description": "Measuring rate of prolonged high sugar while in activity feature",
                    "timeFrame": "From baseline to study completion, up to 12 months"
                },
                {
                    "measure": "Incidence rate of prolonged hyperglycemia (events per person months)",
                    "description": "Measuring the occurrence of prolonged hyperglycemia",
                    "timeFrame": "From baseline to study completion, up to 12 months"
                },
                {
                    "measure": "Incidence rate of prolonged hyperglycemia (events per person months) during usage of a Target Glucose of 140 mg/dL or 150 mg/dL",
                    "description": "Measuring the occurrence of prolonged hyperglycemia while at a set target glucose of 140mg/dL or 150mg/dL",
                    "timeFrame": "From baseline to study completion, up to 12 months"
                },
                {
                    "measure": "Glucose Outcomes during the 4-hour post-bolus period using the SmartBolus Calculator: o Percentage of time < 54 mg/dL o Percentage of time in range 70-180 mg/dL",
                    "description": "Glucose metric from study CGM",
                    "timeFrame": "From baseline to study completion, up to 12 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Self-reported type 1 diabetes\n2. Prescribed, obtained, and have been using the Omnipod 5 System for no more than two weeks or plan to start using the system within the next two weeks\n3. Willing to use only the following types of U-100 insulin during the study: Humalog U-100, Novolog, or Admelog\n4. Able to read and speak English or Spanish (when available) fluently and reside full time in the United States\n5. Willing to collect A1C samples using a provided home kit and send the samples to the registry specific core laboratory at baseline and 3, 6, 9 and 12 months\n6. Willing and able to complete registry assessments every two weeks\n7. Willing and able to complete registry outcome questionnaires at baseline, 6 months and end of study (or at withdrawal)\n8. Is not currently pregnant or planning to become pregnant in the next 12 months and is using a reliable form of birth control\n9. Access to internet via phone, tablet and/or computer to use the registry online platform\n10. Willing to provide CGM and insulin delivery data collected prior to using the Omnipod 5 System, if available (participants will not be excluded if data is not provided)\n11. Willing and able to provide informed consent (or assent) and/or has a parent/guardian willing and able to provide informed consent as applicable\n\nExclusion Criteria:\n\n1. Diagnosed with sickle cell anemia and/or hemoglobinopathy\n2. Planned blood transfusions over the course of the study or has received a blood transfusion within 3 months prior to starting on Omnipod 5\n3. Adults that are unable to provide informed consent",
            "sex": "ALL",
            "minimumAge": "2 Years",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "All new users for the Omnipod 5 System will be required to register with Insulet's Podder Central. Users already in Podder Central will be required to log into their account before logging into the Omnipod 5 Controller if transitioning to the Omnipod 5 System.\n\nA minimum of 2,200 Type 1 participants will be recruited.",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Trang Ly, MBBS, PhD",
                    "role": "CONTACT",
                    "phone": "978-600-7628",
                    "email": "tly@insulet.com"
                },
                {
                    "name": "Julie Perkins",
                    "role": "CONTACT",
                    "phone": "978-600-7951",
                    "email": "jperkins@insulet.com"
                }
            ],
            "locations": [
                {
                    "facility": "Circuit Clinical",
                    "status": "RECRUITING",
                    "city": "Buffalo",
                    "state": "New York",
                    "zip": "14203",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Carmina VanHAll",
                            "role": "CONTACT",
                            "phone": "603-309-7690",
                            "email": "cvanhall@circuitclinical.com"
                        },
                        {
                            "name": "Ashok Subramanian, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.88645,
                        "lon": -78.87837
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003920",
                    "term": "Diabetes Mellitus"
                },
                {
                    "id": "D000003922",
                    "term": "Diabetes Mellitus, Type 1"
                }
            ],
            "ancestors": [
                {
                    "id": "D000044882",
                    "term": "Glucose Metabolism Disorders"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7117",
                    "name": "Diabetes Mellitus, Type 1",
                    "asFound": "Type 1 Diabetes",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7115",
                    "name": "Diabetes Mellitus",
                    "asFound": "Diabetes",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M25403",
                    "name": "Glucose Metabolism Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M10365",
                    "name": "Insulin",
                    "relevance": "LOW"
                },
                {
                    "id": "M173166",
                    "name": "Insulin, Globin Zinc",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hypo",
                    "name": "Hypoglycemic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}